Bristol-Myers Squibb drops plans for Opdivo-Yervoy lung cancer combo
Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns
Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps
Bristol-Myers Squibb Co. is no longer seeking accelerated approval in the U.S. for its Opdivo-Yervoy combination in first-line lung cancer.
The company based the decision on a "review of data available at this time," it said in a news release. It added that it would not be providing additional details in order to protect the integrity of ongoing registrational studies.
